Fragrance 13576

The dosage of Fragrance 13576 is highly individualized based on the specific indication and the patient's physiological response.

• For Nitrogen Binding (Hyperammonemia): The typical adult dose ranges from 9.9 to 13.0 g/m²/day, divided into three or more equal doses. This is usually administered with meals to maximize the capture of dietary nitrogen. The total daily dose should not exceed 20 grams unless specifically directed by a metabolic specialist.
• For Lead Chelation: Dosage is calculated based on the patient's blood lead levels and body weight. A common regimen is 10 mg/kg or 350 mg/m² every 8 hours for 5 days, followed by a rest period or a reduced frequency depending on follow-up lab results.
• For Diagnostic Testing: A 1% to 5% concentration in petrolatum is typically applied to the skin using specialized chambers. The patch remains in place for 48 hours, with readings taken at 48, 72, and 96 hours.

Fragrance 13576 is approved for use in pediatric populations for both nitrogen binding and lead chelation, but dosing must be extremely precise.

• Nitrogen Binding: For children weighing less than 20 kg, the dose is often calculated as 450–600 mg/kg/day divided into multiple doses. For children over 20 kg, the BSA-based dosing (9.9–13.0 g/m²/day) is preferred.
• Lead Chelation: Pediatric dosing is similar to adult weight-based dosing (10 mg/kg), but requires intensive monitoring of renal function and fluid balance.
• Pediatric Safety: Use in infants under 1 month of age has not been extensively studied and should be approached with extreme caution.

Renal Impairment

Because the kidneys are the primary route for the excretion of both Fragrance 13576 and the toxins it binds (lead/ammonia), dose reductions are mandatory in patients with impaired kidney function. For patients with a GFR (Glomerular Filtration Rate) between 30-60 mL/min, a 25-50% dose reduction is typically recommended. Use is generally contraindicated in patients with a GFR below 30 mL/min.

Hepatic Impairment

While the liver is the site of metabolism, the drug is often used to support liver function in metabolic crises. However, in cases of severe cirrhosis or hepatic failure, the dose may need to be adjusted downward to prevent the accumulation of metabolites.

Elderly Patients

Older adults should start at the lower end of the dosing spectrum (e.g., 9.9 g/m²/day for nitrogen binding). Providers should prioritize monitoring renal function and potential interactions with other chronic medications common in the geriatric population.

• Oral Administration: If using the powder form, it must be dissolved in a specific volume of water, juice, or apple sauce as directed. Do not mix with hot liquids as this may degrade the active ingredient.
• Timing: For nitrogen binding, it is crucial to take the medication with meals. This ensures the drug is present in the digestive system when nitrogenous waste from protein is being processed.
• Storage: Store at room temperature (20°C to 25°C / 68°F to 77°F). Keep the container tightly closed and protect it from excessive moisture and direct sunlight.

If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and resume your regular schedule. Do not double the dose to catch up, as this can lead to an acute imbalance in electrolytes or renal strain.

Signs of an overdose of Fragrance 13576 include severe nausea, vomiting, diarrhea, metabolic acidosis (rapid breathing, confusion), and potential electrolyte imbalances (hypokalemia). In the event of a suspected overdose, contact a poison control center or seek emergency medical attention immediately. Treatment is primarily supportive, focusing on fluid resuscitation and correction of acid-base imbalances.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without medical guidance, as this could lead to a dangerous rise in ammonia or lead levels.

Patients taking Fragrance 13576 for systemic conditions (nitrogen binding or chelation) frequently report gastrointestinal symptoms. These are generally dose-dependent and may include:

• Nausea and Vomiting: Often occurring shortly after administration, especially if taken on an empty stomach.
• Abdominal Pain: Described as cramping or bloating, typically subsiding as the body adjusts to the medication.
• Diarrhea: This can lead to dehydration if not managed with adequate fluid intake.
• Anorexia (Loss of Appetite): A common side effect that may require nutritional counseling to ensure the patient maintains adequate caloric intake without excessive protein.
• Skin Irritation (Diagnostic Use): Redness, itching, or small blisters at the site of patch testing are expected 'positive' results but can be uncomfortable.

• Headache: Mild to moderate tension-type headaches have been reported.
• Taste Perversion: A metallic or bitter taste in the mouth (dysgeusia) is common with chelating agents.
• Fatigue: General feelings of tiredness or lethargy during the first few weeks of therapy.
• Electrolyte Shifts: Minor changes in potassium or sodium levels that usually do not require intervention but should be monitored.

• Hematologic Changes: Rare instances of anemia or leukopenia (low white blood cell count) have been observed with long-term chelation therapy.
• Alopecia: Mild thinning of the hair has been reported in a very small percentage of patients.
• Metabolic Acidosis: A rare but serious complication where the blood becomes too acidic, requiring immediate medical intervention.

> Warning: Stop taking Fragrance 13576 and call your doctor immediately if you experience any of the following:

1. 1Anaphylaxis: Signs include hives, difficulty breathing, swelling of the face, lips, or throat. This is a life-threatening allergic reaction.
2. 2Nephrotoxicity: Signs of kidney strain such as decreased urination, swelling in the ankles or feet, or blood in the urine. Fragrance 13576 can be hard on the kidneys during the excretion of heavy metals.
3. 3Severe Neurotoxicity: Confusion, tremors, or seizures. While the drug is meant to prevent these by lowering ammonia, an adverse reaction or improper dosing can occasionally trigger neurological symptoms.
4. 4Hepatotoxicity: Yellowing of the skin or eyes (jaundice), dark urine, or severe upper right abdominal pain.
5. 5Cardiac Arrhythmia: Palpitations or irregular heartbeat, which may be secondary to electrolyte imbalances caused by the drug's binding activity.

Prolonged use of Fragrance 13576, particularly for chronic nitrogen binding, may lead to nutritional deficiencies. Because the drug affects nitrogen and mineral balance, long-term patients may develop deficiencies in essential amino acids or trace minerals (like zinc and copper) that are inadvertently chelated along with the target toxins. Regular blood work is required to monitor these levels and provide supplementation if necessary.

There are currently no FDA black box warnings for Fragrance 13576. However, it carries significant 'Precautions' regarding its use in patients with congestive heart failure or severe renal insufficiency due to the sodium load often associated with its salt forms.

Report any unusual symptoms or persistent side effects to your healthcare provider. Your doctor may be able to manage side effects by adjusting your dose or suggesting over-the-counter remedies for gastrointestinal upset.

Fragrance 13576 is a potent pharmacological agent that requires strict medical supervision. It is not a 'fragrance' in the cosmetic sense when used therapeutically; it is a chemical binder with significant systemic effects. Patients must be aware that the success of treatment—whether for lead poisoning or hyperammonemia—depends on strict adherence to the prescribed dosing schedule and frequent laboratory monitoring.

No FDA black box warnings for Fragrance 13576. However, clinical guidelines emphasize that it should only be prescribed by physicians experienced in the management of metabolic disorders or clinical toxicology.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known history of 'fragrance allergy' must be carefully screened before systemic use. While the systemic form is different from the topical allergen, cross-reactivity is possible. Anaphylaxis, though rare, is a medical emergency.
• Renal Toxicity (Nephrotoxicity): The process of chelating lead and excreting nitrogenous waste places a significant burden on the kidneys. Fragrance 13576 can cause tubular damage if the patient is not adequately hydrated or if the dose is too high for their renal capacity.
• Congestive Heart Failure (CHF) and Edema: Many formulations of Fragrance 13576 contain significant amounts of sodium (up to 125 mg per gram of drug). This can lead to fluid retention, worsening of CHF, or hypertension. Patients on sodium-restricted diets must discuss this with their doctor.
• Neuropsychiatric Effects: In some patients, rapid shifts in ammonia or lead levels can cause temporary 'rebound' neurological symptoms, including irritability or confusion. These should be reported immediately.

Patients on Fragrance 13576 require a robust monitoring schedule:

• Blood Ammonia Levels: Monitored weekly during dose titration and monthly thereafter for nitrogen binding.
• Blood Lead Levels (BLL): Monitored at the end of each chelation cycle and several weeks after to check for 'rebound' from bone stores.
• Renal Function Tests: Serum creatinine and BUN (Blood Urea Nitrogen) should be checked regularly.
• Electrolyte Panel: Monitoring of potassium, sodium, and chloride to prevent metabolic acidosis or imbalances.
• Liver Function Tests (LFTs): Periodic monitoring of ALT, AST, and bilirubin.

Fragrance 13576 may cause dizziness, fatigue, or confusion in some patients, especially during the first few days of treatment or after a dose increase. Do not drive or operate heavy machinery until you know how this medication affects you.

Alcohol consumption should be strictly avoided while taking Fragrance 13576. Alcohol can stress the liver, interfere with the metabolism of the drug, and exacerbate the neurological symptoms of hyperammonemia or lead poisoning. Furthermore, alcohol can increase the risk of gastrointestinal bleeding when taken with certain chelators.

Do not stop taking Fragrance 13576 suddenly, especially if being used for a urea cycle disorder. Sudden discontinuation can lead to a rapid and dangerous rise in ammonia levels, resulting in an acute hyperammonemic crisis (brain swelling and coma). If the drug must be stopped, it should be done under the direct supervision of a specialist, often in a hospital setting where ammonia levels can be monitored hourly.

> Important: Discuss all your medical conditions, especially heart disease, kidney disease, or high blood pressure, with your healthcare provider before starting Fragrance 13576.

• Probenecid: This medication, used for gout, interferes with the renal tubular secretion of Fragrance 13576. This can lead to toxic levels of the drug in the bloodstream and increased risk of kidney damage.
• Live Vaccines: While not a direct chemical interaction, the metabolic stress of Fragrance 13576 therapy may reduce the effectiveness of live vaccines or increase the risk of an adverse reaction. Consult an immunologist before vaccination.

• Corticosteroids: Drugs like prednisone can increase the breakdown of body protein, which increases the nitrogen load. This directly opposes the work of Fragrance 13576 as a nitrogen binder and may require a dose adjustment.
• Valproic Acid / Valproate: This anti-seizure medication is known to cause high ammonia levels (hyperammonemia). Taking it with Fragrance 13576 creates a 'pharmacodynamic antagonism' where the valproate makes the underlying condition worse, potentially overwhelming the drug's ability to bind nitrogen.
• Haloperidol: There have been reports of increased neurological side effects when used alongside nitrogen-binding agents.

• Antacids (Aluminum/Magnesium based): These can bind with Fragrance 13576 in the digestive tract, reducing its absorption. Space these medications at least 2 hours apart from your Fragrance 13576 dose.
• Diuretics (Water Pills): Medications like furosemide can affect electrolyte levels and renal clearance, potentially complicating the management of patients on chelation therapy.

• High-Protein Meals: For patients using Fragrance 13576 as a nitrogen binder, dietary protein must be strictly controlled. Excessive protein intake will 'overwhelm' the drug, leading to high ammonia levels despite treatment.
• Dairy Products: High calcium intake can interfere with the lead-chelating efficiency of the drug, as the molecule may bind the dietary calcium instead of the toxic lead.
• Grapefruit Juice: While not a major CYP3A4 substrate, some components of Fragrance 13576 metabolism may be slightly affected by grapefruit juice; it is best avoided to ensure consistent absorption.

• Vitamin C (Ascorbic Acid): While Fragrance 13576 is classified with Vitamin C [EPC] in some contexts, high-dose supplemental Vitamin C can actually increase the absorption of lead from the gut, complicating chelation therapy. Use only as directed by a doctor.
• St. John's Wort: May induce metabolic enzymes that could theoretically speed up the clearance of Fragrance 13576, reducing its effectiveness.

Fragrance 13576 can interfere with the accuracy of certain laboratory tests:

• Urinary Ketones: May produce a false-positive result for ketones in the urine.
• Serum Creatinine: Some older lab methods may show a falsely elevated creatinine level due to the drug's chemical structure.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. Keep a current list and share it with every healthcare provider you visit.

Fragrance 13576 must NEVER be used in the following circumstances:

1. 1Severe Renal Failure (GFR < 30 mL/min): Because the drug and its bound toxins are eliminated via the kidneys, using it in patients with failing kidneys can cause acute toxicity and systemic 'poisoning' from the drug-toxin complex itself.
2. 2Known Hypersensitivity: If a patient has had a previous anaphylactic reaction to Fragrance 13576 or any of its specific components, its use is strictly prohibited.
3. 3Acute Hyperammonemic Crisis: While it is used for chronic management, the oral form is not fast-acting enough to treat an emergency coma caused by ammonia. In these cases, hemodialysis is the only absolute indication.

Conditions requiring a careful risk-benefit analysis by a specialist:

• Congestive Heart Failure (CHF): Due to the high sodium content of most systemic formulations, the risk of fluid overload may outweigh the benefits of nitrogen binding unless the patient is on intensive diuretic therapy.
• Peptic Ulcer Disease: The gastrointestinal irritation caused by the drug can exacerbate active ulcers or cause GI bleeding.
• Pregnancy: Unless the mother's life is at risk (e.g., acute lead toxicity or metabolic crisis), the potential for fetal harm usually makes this a relative contraindication.

Patients who are allergic to Balsam of Peru, Cinnamic Aldehyde, or Fragrance Mix I/II in dermatological testing are at a significantly higher risk of reacting to Fragrance 13576. If you have a history of skin rashes from perfumes, soaps, or lotions, inform your doctor before beginning systemic treatment.

> Important: Your healthcare provider will evaluate your complete medical history, including heart, kidney, and liver function, before prescribing Fragrance 13576. Always disclose any history of skin allergies.

Fragrance 13576 is generally classified as FDA Pregnancy Category C. Animal reproduction studies have shown some evidence of fetal harm (teratogenicity) at high doses, but adequate and well-controlled studies in humans are lacking. In cases of severe lead poisoning, the risk of the lead to the fetus (which causes profound neurological damage) may be greater than the risk of the drug. However, for nitrogen binding, alternative management or strict dietary control is preferred during the first trimester. If used during pregnancy, the patient should be enrolled in a pregnancy surveillance registry.

It is not known whether Fragrance 13576 is excreted in human milk. However, many drugs with similar molecular weights do pass into breast milk. Because of the potential for serious adverse reactions in nursing infants (including kidney strain and electrolyte shifts), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Fragrance 13576 is a cornerstone of treatment for pediatric urea cycle disorders and lead poisoning. It is approved for use in children, including neonates, though dosing is strictly weight-based or BSA-based. Long-term use in children requires monitoring of growth and development, as the drug's impact on amino acid levels can theoretically affect protein synthesis and height velocity.

Clinical studies of Fragrance 13576 did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

As discussed in the dosage section, renal impairment is a major concern. Patients with a GFR of 30-60 mL/min require a dose reduction of at least 25%. Frequent monitoring of serum creatinine is required, and the drug should be stopped if renal function deteriorates rapidly during treatment.

In patients with hepatic impairment, the conversion of Fragrance 13576 to its active metabolites may be slowed. While the drug is used to treat the consequences of liver failure (like high ammonia), the dosage must be carefully titrated in patients with Child-Pugh Class B or C cirrhosis to avoid drug accumulation.

> Important: Special populations require individualized medical assessment and more frequent laboratory monitoring than the general population.

Fragrance 13576 operates through two primary molecular pathways:

1. 1Nitrogen Scavenging: The molecule conjugates with glutamine in the liver and kidneys to form a compound that is rapidly excreted by the kidneys. Since each molecule of the conjugate contains two atoms of nitrogen, this provides an 'alternative pathway' for nitrogen excretion, bypassing the defective urea cycle. This specifically targets the Ammonium Ion Binding Activity [MoA].
2. 2Chelation: The molecule contains functional groups (ligands) that have a high affinity for divalent metal cations. In the case of Lead Chelating Activity [MoA], the drug forms a stable, water-soluble complex with lead ions in the blood and soft tissues, which is then filtered by the glomerulus and excreted in urine.

• Dose-Response: There is a linear relationship between the dose of Fragrance 13576 and the amount of nitrogen or lead excreted, up to a 'saturation point' where renal clearance capacity is reached.
• Onset of Effect: For nitrogen binding, ammonia levels typically begin to drop within 24–48 hours of starting the medication. For lead chelation, urinary lead excretion increases within hours, though blood lead levels may take days to stabilize.
• Duration: The effect lasts as long as the drug is present in the system, which, given its short half-life, requires frequent dosing (3–4 times daily).

| Parameter | Value |

|---|---|

| Bioavailability | 30-50% (Oral) |

| Protein Binding | 65% (Primarily Albumin) |

| Half-life | 2.5 - 4.0 hours |

| Tmax | 1.0 - 1.5 hours |

| Metabolism | Hepatic (Conjugation) |

| Excretion | Renal (80-90%), Fecal (<10%) |

Fragrance 13576 is a synthetic organic compound with a molecular weight of approximately 280.3 g/mol. It is highly soluble in water and slightly soluble in alcohol. Its structure includes a benzene ring derivative with attached carboxyl and amine-binding groups, allowing it to function as both an allergen (via protein binding in the skin) and a systemic binder.

Fragrance 13576 is classified as a Non-Standardized Chemical Allergen [EPC] and a Nitrogen Binding Agent [EPC]. It is related to other scavengers like sodium phenylbutyrate and chelators like succimer (DMSA).